Devenport J - Search Results

1

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J. Bykerk VP, et al. Among authors: devenport j. Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26. Clin Rheumatol. 2019. PMID: 31028551

2

Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.

Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Strand V, et al. Among authors: devenport j. Rheumatology (Oxford). 2012 Oct;51(10):1860-9. doi: 10.1093/rheumatology/kes131. Epub 2012 Jun 28. Rheumatology (Oxford). 2012. PMID: 22753773 Free PMC article. Clinical Trial.

3

Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC. Weinblatt ME, et al. Among authors: devenport j. Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71. doi: 10.1002/acr.21847. Arthritis Care Res (Hoboken). 2013. PMID: 22972745 Free article. Clinical Trial.

4

Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).

Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. Yazici Y, et al. Clin Exp Rheumatol. 2013 May-Jun;31(3):358-64. Epub 2013 Jan 10. Clin Exp Rheumatol. 2013. PMID: 23305631 Clinical Trial.

5

Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.

Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Keystone EC, et al. J Rheumatol. 2014 Feb;41(2):216-26. doi: 10.3899/jrheum.130489. Epub 2014 Jan 15. J Rheumatol. 2014. PMID: 24429164 Free article. Clinical Trial.

6

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.

Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. Reiss WG, et al. Rheumatol Int. 2016 Feb;36(2):295-300. doi: 10.1007/s00296-015-3285-2. Epub 2015 May 31. Rheumatol Int. 2016. PMID: 26026604 Free PMC article. Clinical Trial.

7

Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.

Wang J, Devenport J, Low JM, Yu D, Hitraya E. Wang J, et al. Among authors: devenport j. Arthritis Care Res (Hoboken). 2016 Jun;68(6):882-5. doi: 10.1002/acr.22765. Arthritis Care Res (Hoboken). 2016. PMID: 26473986 Free PMC article.

8

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.

Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M. Kivitz A, et al. Among authors: devenport j. Rheumatol Ther. 2016 Dec;3(2):291-304. doi: 10.1007/s40744-016-0043-1. Epub 2016 Sep 24. Rheumatol Ther. 2016. PMID: 27747585 Free PMC article.

9

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Pethö-Schramm A. Choy E, et al. Among authors: devenport j. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. Rheumatology (Oxford). 2019. PMID: 30649524 Free PMC article.

10

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Safy-Khan M, Jacobs JWG, de Hair MJH, Welsing PMJ, Edwardes MD, Teitsma XM, Luder Y, Devenport J, van Laar JM, Pethoe-Schramm A, Bijlsma JWJ. Safy-Khan M, et al. Among authors: devenport j. Ann Rheum Dis. 2020 Apr;79(4):460-463. doi: 10.1136/annrheumdis-2019-216537. Epub 2020 Feb 7. Ann Rheum Dis. 2020. PMID: 32033935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page